These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38532270)

  • 1. A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.
    Decker RL; Steven Ernest C; Radtke DB; Wang R; Araújo J; Keller SY; Zhang X
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):970-981. PubMed ID: 38532270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
    Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
    Kim H; Brooks KM; Tang CC; Wakim P; Blake M; Brooks SR; Montealegre Sanchez GA; de Jesus AA; Huang Y; Tsai WL; Gadina M; Prakash A; Janes JM; Zhang X; Macias WL; Kumar P; Goldbach-Mansky R
    Clin Pharmacol Ther; 2018 Aug; 104(2):364-373. PubMed ID: 29134648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data.
    Nassar-Sheikh Rashid A; Hooijberg F; Bergkamp SC; Gruppen MP; Kuijpers TW; Nurmohamed M; Rispens T; Wolbink G; van den Berg JM; Schonenberg-Meinema D; Mathôt RAA
    Paediatr Drugs; 2024 Jul; 26(4):441-450. PubMed ID: 38630199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
    Zhao X; Sheng XY; Payne CD; Zhang X; Wang F; Cui YM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):952-960. PubMed ID: 32945153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Emery P; Tanaka Y; Cardillo T; Schlichting D; Rooney T; Beattie S; Helt C; Smolen JS
    Arthritis Res Ther; 2020 May; 22(1):115. PubMed ID: 32414425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
    Zhang X; Chua L; Ernest C; Macias W; Rooney T; Tham LS
    CPT Pharmacometrics Syst Pharmacol; 2017 Dec; 6(12):804-813. PubMed ID: 28891251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
    Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of baricitinib in patients with rheumatoid arthritis.
    Honda S; Harigai M
    Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
    [No Abstract]   [Full Text] [Related]  

  • 12. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
    Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
    Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
    Ruperto N; Brunner HI; Zuber Z; Tzaribachev N; Kingsbury DJ; Foeldvari I; Horneff G; Smolewska E; Vehe RK; Hazra A; Wang R; Mebus CA; Alvey C; Lamba M; Krishnaswami S; Stock TC; Wang M; Suehiro R; Martini A; Lovell DJ; ;
    Pediatr Rheumatol Online J; 2017 Dec; 15(1):86. PubMed ID: 29282090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
    Leu JH; Shiff NJ; Clark M; Bensley K; Lomax KG; Berezny K; Nelson RM; Zhou H; Xu Z
    Paediatr Drugs; 2022 Nov; 24(6):699-714. PubMed ID: 36171515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
    Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
    Schlueter M; Rouse P; Pitcher A; Graham-Clarke PL; Nicolay C; Fakhouri W
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):221-228. PubMed ID: 32212867
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
    Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
    J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis.
    Krishnaswami S; Hutmacher MM; Robbins JL; Bello A; West C; Bloom BJ
    J Clin Pharmacol; 2012 Aug; 52(8):1134-49. PubMed ID: 21878579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Pacheco-Tena C; Louw I; Vega-Cornejo G; Spindler AJ; Kingsbury DJ; Schmeling H; Borzutzky A; Cuttica R; Inman CJ; Malievskiy V; Scott C; Keltsev V; Terreri MT; Viola DO; Xavier RM; Fernandes TAP; Velázquez MDRM; Henrickson M; Clark MB; Bensley KA; Li X; Lo KH; Leu JH; Hsu CH; Hsia EC; Xu Z; Martini A; Lovell DJ;
    Rheumatology (Oxford); 2021 Oct; 60(10):4495-4507. PubMed ID: 33493312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.